21-hydroxylase deficiency pathophysiology

Congenital adrenal hyperplasia main page
21-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 21-Hydroxylase Deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
21-hydroxylase deficiency pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 21-hydroxylase deficiency pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 21-hydroxylase deficiency pathophysiology
CDC on 21-hydroxylase deficiency pathophysiology
21-hydroxylase deficiency pathophysiology in the news
Blogs on 21-hydroxylase deficiency pathophysiology
Directions to Hospitals Treating 21-Hydroxylase Deficiency
Risk calculators and risk factors for 21-hydroxylase deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mehrian Jafarizade, M.D [2], Ahmad Al Maradni, M.D. [3]

Overview

The progression to 21-hydroxylase deficiency usually involves the defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol which results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion. The resulting adrenal stimulation leads to increased production of androgens due to shunting of the pathway to androgen synthesis. More than 95% of cases of congenital adrenal hyperplasia (CAH) are caused by 21-hydroxylase deficiency. The clinical manifestations of congenital adrenal hyperplasia is closely related to the type and severity of disease. The severity of disease relates to the type of mutation which causes enzyme inactivity or hypo-activity. There is a lack of enzyme in classic form of 21-hydroxylase deficiency; while in the non-classic form, enzymatic activity is reduced but sufficient to maintain normal glucocorticoid and mineralocorticoid production. The gene responsible for 21-hydroxylase deficiency is CYP21A. This gene is located within the human leucocyte antigen class III region of chromosome 6. Meiotic recombination occurs in this genomic region as a result of the high degree of sequence homology between CYP21A2 and its pseudogene CYP21A1. Approximately 70% of CYP21A2 genetic mutation is due to gene conversion and micro-deletions in CYP21A1 gene.

Pathophysiology

Pathogenesis

• 21-hydroxylase enzyme is involved in the synthesis of aldosterone in zona glomerulosa and cortisol in zona fasciculata. Lack of 21-hydroxylase enzyme leads to decrease in cortisol and aldosterone levels and the rest of synthesis pathways produce extra androgens and lead to hirsutism.
• More than 95% of all cases of congenital adrenal hyperplasia (CAH) are caused by 21-hydroxylase deficiency; the clinical manifestations of 21-hydroxylase deficiency is closely related to the type and severity of disease.
• The severity of disease relates to the type of mutation, which causes enzyme inactivity or hypo activity.
• There is a lack of enzyme in classic type of 21-hydroxylase deficiency; while in the non-classic form, enzymatic activity is reduced but sufficient to maintain normal glucocorticoid and mineralocorticoid production.

Glucocorticoid pathway

• In patients with 21-hydroxylase deficiency in zona fasciculata, there is a defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol which results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion.

Mineralocorticoids pathway

• In patients with 21-hydroxylase deficiency in zona glomerulosa, there is a defective conversion of progesterone to 11-deoxycortisterone which results in decreased aldosterone synthesis.
• The lack of aldosterone causes large amounts of sodium loss in the urine. Urinary sodium concentrations are more than 50 mEq/L. As a result of high amount of sodium loss, blood volume and blood pressure can not be maintained in normal ranges.
• Due to mineralocorticoid deficiency, potassium and acid excretion are also impaired resulting in hyperkalemia and metabolic acidosis.
• There is significant water loss and symptoms of dehydration due to salt wasting within the first two week of life. In severe form of CAH, vomiting, severe dehydration, circulatory collapse and shockdevelops in the second or third week of life.

Androgen pathway

• In the androgen synthesis pathway, 21-hydroxylase enzyme does not have a direct role; therefore with extra amount of other products from blocked cortisol and aldosterone synthesis, androgen pathway have extra precursor metabolites resulting in androgen excess in the form of dehydroepiandrosterone and androstenedione accumulation.
• On the other hand, lack of cortisol removes the negative feedback on the pituitary gland, resulting in an increase in ACTH level and consequently more increase in androgen synthesis pathway. High androgen level in 21-hydroxylase deficient women during pregnancy causes ambiguous genitalia in female fetus; also in milder forms induces hirsutism and virilization in women. Adrenal androgens produce little effect on the genitalia of male infants with severe CAH. Excess androgen can cause precocious puberty in male child.

Below is the hormonal pathway of adrenal steroids and related enzymes, also the mechanism of 21 hydroxylase deficiency symptoms.

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes

Genetics

• Congenital adrenal hyperplasia subtypes are all autosomal recessive and monogenetic. The disease manifestation follows the allele that results in a more functional enzyme, and generally correlation between genotype and phenotype is good.

CYP21A gene

• The gene responsible for 21-hydroxylase deficiency is CYP21A. This gene is located within the human leucocyte antigen class III region of chromosome 6.

CYP21A gene has two types:

CYP21A2

• An active gene called CYP21A2, which encodes 21-hydroxylase, a cytochrome P450 type II enzyme containing 495 amino acids.

CYP21A1

• This gene is a non-functional pseudogene named CYP21A1 or CYP21P. This pseudogene produces an enzyme with no activity because it lacks eight bases from codons 110-112, which results in a stop codon.

Mutation mechanisms:

• Meiotic recombination events occurs in this genomic region as a result of the high degree of sequence homology between CYP21A2 and its pseudogene CYP21A1.
  • Approximately 70% of disease associated with CYP21A2 is due to gene conversion and microdeletions in CYP21A1 gene.
  • Approximately 25% to 30% are chimeric genes due to large deletions.
  • Approximately 1% to 2% of cases are due to de novo mutations because of high variability of the CYP21A2 locus.
  • Chromosome 6 uniparental disomy is rare cause of 21-hydroxylase deficiency with an unknown prevalence.

• Gene mutations that completely inactivates CYP21A2 gene will result in the classic type and salt-wasting subtype.
• Gene mutations that maintain 1–2% of 21-hydroxylase activity will result in classic type and non-salt-wasting subtype. These patients have minimal aldosterone production that prevents a neonatal adrenal crisis.

Gross Pathology

Gross pathology findings in patients with 21 hydroxylase deficiency are:

• Enlarged adrenal glands
• Wrinkled surface of adrenal glands
• Cerebriform pattern in adrenal glands (pathognomonic sign)
• Normal ultrasound appearance

Microscopic Pathology

In 21-hydroxylase deficiency microscopic findings may include:

• Diffuse cortical hyperplasia with smaller cells
• The cell cytoplasm can be vacuolated, and often more basophilic.
• Rare mitotic figures may be present
• The hyperplastic cells typically lack features of cellular atypia.

Adrenal gland, Cortex - Hyperplasia in a female rat from a chronic study. There is a hyperplastic lesion (H) in which cortical cells are increased in number but are smaller in size than adjacent normal cortical cells (NC)

Adrenal gland, Cortex - Hyperplasia in a male rat from a chronic study. There are two adjacent foci of hyperplasia (H) in the zona fasciculata.

References

Template:WH Template:WS ​